Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Bilzen – page 72

1 415 clinical trials in Bilzen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bilzen at a glance
1 415
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 415 trials in Bilzen

Open in trial search

Hypersomnia

Not recruiting

Study of ALKS 2680 to treat excessive daytime sleepiness in people with idiopathic hypersomnia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

COVID-19

Not recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:ABBV-CLS-628
  • Sponsor:Calico Life Sciences LLC

Breast cancer+2

Not recruiting

Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab
  • Sponsor:Institut Jules Bordet

Sickle cell disease

Not recruiting

Study on the Effects of Tebapivat and AG-946 in Patients with Sickle Cell Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:AG-946 phosphate
  • Sponsor:Agios Pharmaceuticals Inc.

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Study of Tarlatamab Treatment in Patients with Small Cell Lung Cancer: Evaluation of Different Dosing Schedules

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Oral contraception

Not recruiting

Study on the Effectiveness and Safety of Mifepristone 50 mg Weekly for Contraception in Women

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Mifepristone
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Bilzen

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management and optimization strategies for patients with chronic digestive conditions.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn

This primary care investigation evaluates various deprescribing approaches, including on-demand usage and alternative treatments, to improve long-term medication management for patients on chronic PPI therapy.

02 Primary Care Innovation

Advanced research examining optimal medication reduction strategies in the primary care setting, focusing on patient-centered approaches to decrease long-term medication use.

  • Medication Management
  • Treatment Optimization
  • Patient-Centered Care

The study compares traditional dose reduction methods with innovative approaches, including alternative therapeutic options for digestive health management.

03 Therapeutic Alternatives

Investigation into alternative treatment strategies for common digestive conditions, comparing conventional medication tapering with newer therapeutic approaches.

  • Alginate Therapy
  • On-Demand Treatment
  • Medication Reduction

Research focuses on establishing evidence-based protocols for transitioning patients from long-term PPI use to more flexible treatment regimens.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.